|
1
|
Pakzad R, Mohammadian-Hafshejani A,
Khosravi B, Soltani S, Pakzad I, Mohammadian M, Salehiniya H and
Momenimovahed Z: The incidence and mortality of esophageal cancer
and their relationship to development in Asia. Ann Transl Med.
4(29)2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Tan HZ, Lin WJ, Huang JQ, Dai M, Fu JH,
Huang QH, Chen WM, Xu YL, Ye TT, Lin ZY, et al: Updated incidence
rates and risk factors of esophageal cancer in Nan'ao Island, a
coastal high-risk area in southern China. Dis Esophagus. 30:1–7.
2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Lei S, Yang L and Li Y: Epidemiological
characteristics and changing trends of esophageal cancer diagnosed
by gastroscopy in Xijing Hospital from 2016 to 2020. J Hebei Med
Univ. 43:150–154. 2022.(In Chinese).
|
|
4
|
Pennathur A, Gibson MK, Jobe BA and
Luketich JD: Oesophageal carcinoma. Lancet. 381:400–412.
2013.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Dvoretskii SIu, Levchenko EV, Karachun AM,
Komarov IV, Pelipas' Iu V, Avanesian AA, Khandogin NV and Tiuriaeva
EI: Experience of the use of endovideotechnology in surgical
treatment of esophageal cancer. Vestn Khir Im I I Grek. 173:54–59.
2014.PubMed/NCBI(In Russian).
|
|
6
|
Sugimura K, Miyata H, Tanaka K, Takahashi
T, Kurokawa Y, Yamasaki M, Nakajima K, Takiguchi S, Mori M and Doki
Y: High infiltration of tumor-associated macrophages is associated
with a poor response to chemotherapy and poor prognosis of patients
undergoing neoadjuvant chemotherapy for esophageal cancer. J Surg
Oncol. 111:752–759. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Zhu Z, Wang H, Pang Y, Hu H, Zhang H and
Wang W: Exosomal long non-coding RNA UCA1 functions as growth
inhibitor in esophageal cancer. Aging (Albany NY). 12:20523–20539.
2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Maisonpierre PC, Suri C, Jones PF,
Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J,
Aldrich TH, Papadopoulos N, et al: Angiopoietin-2, a natural
antagonist for Tie2 that disrupts in vivo angiogenesis. Science.
277:55–60. 1997.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Saharinen P, Eklund L and Alitalo K:
Therapeutic targeting of the angiopoietin-TIE pathway. Nat Rev Drug
Discov. 16:635–661. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ladeira K, Macedo F, Longatto-Filho A and
Martins SF: Angiogenic factors: Role in esophageal cancer, a brief
review. Esophagus. 15:53–58. 2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Urosevic J, Blasco MT, Llorente A,
Bellmunt A, Berenguer-Llergo A, Guiu M, Canellas A, Fernandez E,
Burkov I, Clapes M, et al: ERK1/2 signaling induces upregulation of
ANGPT2 and CXCR4 to mediate liver metastasis in colon cancer.
Cancer Res. 80:4668–4680. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Lauret Marie Joseph E, Laheurte C, Jary M,
Boullerot L, Asgarov K, Gravelin E, Bouard A, Rangan L, Dosset M,
Borg C and Adotévi O: Immunoregulation and clinical implications of
ANGPT2/TIE2(+) M-MDSC signature in non-small cell lung cancer.
Cancer Immunol Res. 8:268–279. 2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Zhang B, Li N and Zhang H: Knockdown of
homeobox B5 (HOXB5) inhibits cell proliferation, migration, and
invasion in non-small cell lung cancer cells through inactivation
of the Wnt/β-catenin pathway. Oncol Res. 26:37–44. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Hong CS, Jeong O, Piao Z, Guo C, Jung MR,
Choi C and Park YK: HOXB5 induces invasion and migration through
direct transcriptional up-regulation of β-catenin in human gastric
carcinoma. Biochem J. 472:393–403. 2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Lee K, Chang JW, Oh C, Liu L, Jung SN, Won
HR, Kim YI, Rha KS and Koo BS: HOXB5 acts as an oncogenic driver in
head and neck squamous cell carcinoma via EGFR/Akt/Wnt/β-catenin
signaling axis. Eur J Surg Oncol. 46:1066–1073. 2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Li ZX, Wu G, Jiang WJ, Li J, Wang YY, Ju
XM and Yin YT: HOXB5 promotes malignant progression in pancreatic
cancer via the miR-6732 pathway. Cell Cycle. 19:233–245.
2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Feng W, Huang W, Chen J, Qiao C, Liu D, Ji
X, Xie M, Zhang T, Wang Y, Sun M, et al: CXCL12-mediated HOXB5
overexpression facilitates colorectal cancer metastasis through
transactivating CXCR4 and ITGB3. Theranostics. 11:2612–2633.
2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Zhang J, Zhang S, Li X, Zhang F and Zhao
L: HOXB5 promotes the progression of breast cancer through
wnt/beta-catenin pathway. Pathol Res Pract.
224(153117)2021.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Liang J, Li H, Han J, Jiang J, Wang J, Li
Y, Feng Z, Zhao R, Sun Z, Lv B and Tian H: Mex3a interacts with
LAMA2 to promote lung adenocarcinoma metastasis via PI3K/AKT
pathway. Cell Death Dis. 11(614)2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Chang J, Hu X, Nan J, Zhang X and Jin X:
HOXD9-induced SCNN1A upregulation promotes pancreatic cancer cell
proliferation, migration and predicts prognosis by regulating
epithelialmesenchymal transformation. Mol Med Rep.
24(819)2021.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Zhou K, Song B, Wei M, Fang J and Xu Y:
MiR-145-5p suppresses the proliferation, migration and invasion of
gastric cancer epithelial cells via the ANGPT2/NOD_LIKE_RECEPTOR
axis. Cancer Cell Int. 20(416)2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Qi L, Wang ZY, Shao XR, Li M, Chen SN, Liu
XQ, Yan S, Zhang B, Zhang XD, Li X, et al: ISL2 modulates
angiogenesis through transcriptional regulation of ANGPT2 to
promote cell proliferation and malignant transformation in
oligodendroglioma. Oncogene. 39:5964–5978. 2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Xie JY, Wei JX, Lv LH, Han QF, Yang WB, Li
GL, Wang PX, Wu SB, Duan JX, Zhuo WF, et al: Angiopoietin-2 induces
angiogenesis via exosomes in human hepatocellular carcinoma. Cell
Commun Signal. 18(46)2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Lee JY, Hur H, Yun HJ, Kim Y, Yang S, Kim
SI and Kim MH: HOXB5 promotes the proliferation and invasion of
breast cancer cells. Int J Biol Sci. 11:701–711. 2015.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Tucci R, Campos MS, Matizonkas-Antonio LF,
Durazzo M, Pinto Junior Ddos S and Nunes FD: HOXB5 expression in
oral squamous cell carcinoma. J Appl Oral Sci. 19:125–129.
2011.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Gao Y, Fei X, Kong L and Tan X: HOXB5
promotes proliferation, migration, and invasion of pancreatic
cancer cell through the activation of the GSK3β/β-catenin pathway.
Anticancer Drugs. 31:828–835. 2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Asati V, Mahapatra DK and Bharti SK:
PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as
anticancer agents: Structural and pharmacological perspectives. Eur
J Med Chem. 109:314–341. 2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Zhou CF, Liu MJ, Wang W, Wu S, Huang YX,
Chen GB, Liu LM, Peng DX, Wang XF, Cai XZ, et al: miR-205-5p
inhibits human endometriosis progression by targeting ANGPT2 in
endometrial stromal cells. Stem Cell Res Ther.
10(287)2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Zhu R, Ge J, Ma J and Zheng J:
Carcinoembryonic antigen related cell adhesion molecule 6 promotes
the proliferation and migration of renal cancer cells through the
ERK/AKT signaling pathway. Transl Androl Urol. 8:457–466.
2019.PubMed/NCBI View Article : Google Scholar
|
